| Code | CSB-RA023994MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to APG-990, targeting TNFSF4 (Tumor Necrosis Factor Superfamily Member 4), also known as OX40 ligand (OX40L). TNFSF4 is a type II transmembrane glycoprotein primarily expressed on activated antigen-presenting cells, including dendritic cells, B cells, and macrophages. It functions as a critical costimulatory molecule in T cell activation and immune response regulation by binding to its receptor OX40 (CD134) on activated T cells. This interaction promotes T cell proliferation, survival, and cytokine production, playing essential roles in both adaptive immunity and inflammatory processes. Dysregulation of the TNFSF4/OX40 pathway has been implicated in various conditions, including autoimmune diseases, allergic disorders, cancer immunity, and transplant rejection.
APG-990 is a humanized monoclonal antibody targeting TNFSF4. By binding to TNFSF4, it blocks the OX40/OX40L signaling pathway and inhibits the excessive activation of T cell responses, providing a new potential option for the treatment of diseases such as moderate to severe plaque psoriasis. This biosimilar provides researchers with a valuable tool for investigating TNFSF4-mediated immune mechanisms, exploring costimulatory pathway dynamics, and studying potential therapeutic interventions in immunological research models.
There are currently no reviews for this product.